Bone marrow derived mesenchymal stem cells pretreated with erythropoietin accelerate the repair of acute kidney injury

BACKGROUND: Mesenchymal stem cells (MSCs) represent a promising treatment option for acute kidney injury (AKI). The main drawbacks of MSCs therapy, including the lack of specific homing after systemic infusion and early cell death in the inflammatory microenvironment, directly affect the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Song, Qiao, Yu-ming, Liu, Yong-guang, Liu, Ding, Hu, Jian-min, Liao, Jun, Li, Min, Guo, Ying, Fan, Li-pei, Li, Liu-Yang, Zhao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667799/
https://www.ncbi.nlm.nih.gov/pubmed/33292452
http://dx.doi.org/10.1186/s13578-020-00492-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667799/
https://www.ncbi.nlm.nih.gov/pubmed/33292452
http://dx.doi.org/10.1186/s13578-020-00492-2

Ejemplares similares